BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, announced the closing of an $84 million Series B extension, bringing total capital raised by BlossomHill to $257 million to date. Proceeds from the financing will be used to accelerate BlossomHill's two lead clinical programs, BH-30643 (OMNI-EGFRTM inhibitor) and BH-30236 (CLK inhibitor), and to further advance the company's wholly-owned pipeline of intelligently designed cancer medicines.

The Series B extension financing included a select group of new investors, led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, and participation from existing investors including Cormorant Asset Management, OrbiMed, Plaisance Capital Management LLC and Vivo Capital.